Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 13/20 | 0.67 |
| ▸ | ACE | P12821 | 6/20 | 0.67 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21221274 | 1.00 | MME (0.67) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18574632 | 0.91 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059568 | 0.91 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL489040 | 0.91 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL8214132 | 0.91 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL1908525 | 0.91 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL22420467 | 0.91 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL2707112 | 0.91 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059569 | 0.91 | MME (0.77) | MMEACEMMEL1 | |
| SCHEMBL21221277 | 0.91 | MME (0.66) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | claimed |
| EP-3778557-A1 | COMBINATIONS COMPRISING A SUBSTITUTED BIPHENYLBUTANOIC ESTER DERIVATIVE AS NEP INHIBITOR AND VALSARTAN | Novartis AG (CH) | 2021-02-17 | — | — | EP | claimed |
| CN-111655671-A | Substituted bisphenyl butyrate derivatives as NEP inhibitors | 诺华股份有限公司 | 2020-09-11 | — | — | CN | claimed |
| EP-3544966-B1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2020-09-09 | — | — | EP | claimed |
| US-20200246295-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2020-08-06 | — | — | US | claimed |
| US-10668035-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2020-06-02 | — | — | US | claimed |
| US-20190240177-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2019-08-08 | — | — | US | claimed |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | disclosed |
| EP-3778557-A1 | COMBINATIONS COMPRISING A SUBSTITUTED BIPHENYLBUTANOIC ESTER DERIVATIVE AS NEP INHIBITOR AND VALSARTAN | Novartis AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| CN-111655671-A | Substituted bisphenyl butyrate derivatives as NEP inhibitors | 诺华股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3544966-B1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2020-09-09 | — | — | EP | disclosed |
| US-20200246295-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2020-08-06 | — | — | US | disclosed |
| US-10668035-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2020-06-02 | — | — | US | disclosed |
| US-20190240177-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | MME, REN, ECE1 | MME 1/4885ACE 4/4885MMEL1 606/4885 |
| US-10668035-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | MME, REN, ECE1 | MME 1/4885ACE 4/4885MMEL1 606/4885 |
| US-20200246295-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | MME, REN, ECE1 | MME 1/4885ACE 4/4885MMEL1 606/4885 |
| US-20190240177-A1 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | MME, REN, ECE1 | MME 1/4885ACE 4/4885MMEL1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.